SynthesisJournal of gastrointestinal cancer2025
Does Malignant Ascites Define Prognosis in Gastric Cancer with Peritoneal Spread? A Systematic Review and Meta-analysis.
Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the fifth most common cancer and a leading cause of cancer-related death. Peritoneal metastases occur in up to 25% of patients, with nearly half developing malignant ascites (MA), which arises from lymphatic obstruction, vascular permeability, and immune dysregulation. Median overall survival (OS) in this setting is poor (2-8 months). This systematic review and meta-analysis evaluate the prognostic impact of ascites in metastatic GC. MATERIALS AND
methodsPubMed, Embase, and Cochrane were searched for studies reporting OS in metastatic GC patients with and without ascites. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using fixed and random-effects models in RStudio 4.2.3.
resultsOverall, 14 studies involving 2179 patients, with 1208 having ascites, were included in the analysis. Of these, 13 were retrospective studies and 1 was a prospective study. The presence of ascites was associated with a significantly worse prognosis compared to its absence (HR 1.8418; 95% CI 1.5657-2.1667; P < 0.001). Similarly, the comparison of massive type ascites with mild to moderate type shows a worse outcome for the higher grade of ascites (HR 1.8597; 95% CI 1.4633-2.3635; P < 0.001). Comparing no to moderate ascites vs massive ascites, the massive type also shows a significantly lower overall survival (HR 2.5114; 95% CI 1.5409-4.0931; P < 0.001).
conclusionsThis meta-analysis suggests that the presence of ascites and its grades are essential prognostic factors for metastatic gastric cancer, significantly worsening overall survival.
Indexed as
Identifiers
41099972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.